Your session is about to expire
← Back to Search
Study Summary
This trial is testing the safety and effectiveness of the Cordella Pulmonary Artery Sensor System in patients with heart failure. There are five groups in the study, each with a different approach to using the
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available positions for patients to participate in this clinical trial?
"Indeed, the information available on clinicaltrials.gov indicates that this trial is actively seeking individuals to participate. The initial posting of the trial took place on November 29th, 2023 and it was most recently updated on December 21st, 2023. Across five different locations or sites, a total of 1650 participants are being sought for enrollment in the study."
In the Canadian region, are there numerous medical facilities currently conducting this study?
"Patients are currently being enrolled at Methodist San Antonio in Texas, Heart Care Centers of Illinois (HCCI) in Palos Park, Illinois, and Ascension Sacred Heart in Pensacola, Florida. Furthermore, the trial is also taking place at five additional undisclosed locations."
What is the current number of individuals enrolled in this clinical research study?
"To adequately conduct this study, a total of 1650 individuals who meet the eligibility criteria are needed. The trial will be overseen by the sponsor, Endotronix Inc., and conducted at various locations including Methodist San Antonio in San Antonio, Texas and Heart Care Centers of Illinois (HCCI) in Palos Park, Illinois."
What are the intended results that researchers hope to achieve through this medical study?
"The main objective of this study, spanning approximately 24 months, is to evaluate the safety and freedom from device/system related complications in the randomized arm. Secondary outcomes include assessing efficacy through HF hospitalizations (length of stay), functional status improvement as measured by NYHA classification and 6MWT, and safety with regards to freedom from device/system related complications at 12 months."
Share this study with friends
Copy Link
Messenger